US FDA Approves Subcutaneous Sarclisa for Multiple Myeloma Across All Existing Indications
Sanofi’s SC formulation becomes the first oncology therapy approved for administration via both an on-body injector and manual subcutaneous injection, offering shorter treatment times for patients.
Multiple Myeloma | 13/07/2026 | By News Bureau
GSK plc Secures China Approval for Blenrep Combination Therapy in Multiple Myelom
National Medical Products Administration approves Blenrep with bortezomib and dexamethasone for relapsed or refractory patients, backed by strong phase III trial outcomes.
Multiple Myeloma | 21/04/2026 | By News Bureau | 108
Biocon Biologics Secures US FDA Approval for Denosumab Biosimilars Bosaya and Aukelso
The US Food and Drug Administration (FDA) has approved Biocon Biologics' denosumab biosimilars, Bosaya (denosumab-kyqq) 60 mg/mL injection in a single-dose prefilled syringe (PFS) and Aukelso (denosumab-kyqq) 120 mg/1.7 mL (70 mg/mL) injection in a single-dose vial, biosimilars of Prolia and Xgeva, respectively.
Multiple Myeloma | 17/09/2025 | By Dineshwori | 486
Amneal Launches BORUZU for Multiple Myeloma and Mantle Cell Lymphoma
BORUZU™ (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma.
Multiple Myeloma | 07/04/2025 | By Aishwarya | 310
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy